B1/AMP-activated protein kinase (LKB1/AMPK) signaling pathway was analyzed using immunoblotting, immunoprecipitation, siRNA silencing and plasmid overexpression.
INTRODUCTION AND OBJECTIVES:
The combination of radiation therapy (RT) and androgen deprivation therapy (ADT) is superior to RT alone for treatment of patients with clinically localized, intermediate and high-risk prostate cancer. ADT acts to prevent the androgen receptor (AR) from promoting DNA damage repair (DDR), which thereby increases RT-mediated cell kill. Emerging evidence supports that AR variants can mediate DDR following RT allowing for increased cell survival. Further studies have demonstrated that irradiation of prostate cancer cells trigger binding of androgen receptors to the catalytic subunit of the critical DNA repair kinase DNA-PK (DNA-PKc). We set to study if the influence of DNA-PKc in RT-induced DNA damage of prostate cancer cells.
METHODS: Using a prostate cancer cell line and a DNA-PKc inhibitor NU7441, cells were subjected to irradiation (IR) and the amount of damaged DNA was visualized with comet assays. The quantification of DNA damage was further evaluated with quantitative immunofluorescence of gamma-H2AX and 53BP1. To validate these findings in vivo, we established subcutaneous R1-D567 xenografts in Nu/Nu mice. When tumors reached 200mm3, mice were castrated and treated with NU7441, followed by 2Gy radiation. Treatment groups were compared for tumor growth.
RESULTS: Pretreatment with NU7441 enhanced IR DNA damage with increased olive tail movement on comet assay. This was supported by the persistence of double-stranded breaks after IR as shown in Figure 1A . This demonstrated in vitro that DNA-PKc inhibition was associated with increased IR-induced DNA damage.The results of our in vivo model validated our findings. The combination of IR and NU7441 was more effective in slowing the tumor growth than control when assessed by split-plot ANOVA (p<0.001). DNA damage in these cells were again quantified by significant persistence of gamma-H2AX and 53BP1 after IR (p<0.001).
CONCLUSIONS: DNA-PKc is critical for DNA repair mechanisms following IR and that the combined blockade of AR and DNA-PKc enhances IR-mediated cell kill. This data establishes the molecular rationale for a potential clinical trial combining agents targeting DNAPKc in combination with RT for patients with clinically localized prostate cancer. 
In recent years, it has become evident, that the different cell populations comprising the tumor microenvironment contribute substantially to carcinogenesis, local tumor growth and metastatic spread. Especially the tumor-promoting roles of cancer-associated fibroblasts have been the focus of several elaborate in-vitro studies. However, evidence from representative invivo models is scarce. In this study, we coinjected prostate cancer (PCa) cells together with different populations of prostate fibroblasts (cancer-associated (CAF), not cancer-associated (NCAF), benign prostate hyperplasia associated (BPHF)) and examined their impact on local tumor growth and the development of metastases.
METHODS: We isolated fibroblast primary cultures from tumorbearing (CAF) and tumor-free (NCAF) tissue samples of a radical prostatectomy specimen as well as from tissue samples of a transvesical prostate adenoma enucleation (BPHF). 5x10 5 CAF/NCAF/ BPHF cells were injected into the prostate of SCID mice together with 5x10 5 LuCaP136 spheroids or LNCaP cells (n¼8 for each group). Tumor growth was monitored by ultrasonography, micro-CT, 9.4T MRI and serum PSA-measurements. Animals were sacrificed after 10 weeks.
RESULTS: The coinjection of CAFs fostered tumor growth in LuCaP136 but not in LNCaP xenografts. Primary tumor volumes as well as serum PSA values were significantly higher in LuCaP136þCAF mice compared to LuCaP136þNCAF and LuCaP136þBPHF mice (p<0.01 for each time point). Significantly more lymph node metastases (LN mets) were seen in LuCaP136þCAF mice (one mouse without, four mice with 2 and three mice with ¼3 LN mets) compared to LuCaP136þNCAF (one mouse without, four mice with 1 and one mouse with 2 LN mets) and LuCaP136þBPHF mice (two mice without, three mice with 1 and two mice with 2 LN mets) (p<0.01). Furthermore, pulmonary metastases were observed more often in LuCaP136 and LNCaP xenografts when PCa cells were coinjected with CAFs (57% for LuCaP136, 71% for LNCaP) as compared to coinjection with NCAFs (0% for LuCaP136, 29% for LNCaP) and BPHFs (14% for LuCaP136, 29% for LNCaP).
CONCLUSIONS: Using a representative orthotopic xenograft model and patient-derived fibroblast cultures it could be shown that CAFs play a crucial role in local and systemic PCa progression by stimulating primary tumor growth and metastatic spread to the lymph nodes and lungs. However, some of the effects were cell-line specific.
